Physician profile
Julia C Lee
NPI 1093280604
$7,008.09
in general payments reported to CMS, 2019-2025
29 companies · $2,907 in 2025
The $2,907 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $328 · 2023: $1,615 · 2024: $2,158 · 2025: $2,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,593 · Education: $87.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,592.84 |
| Education | $87.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,176.37 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $812.29 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $540.58 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $501.13 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $408.90 | 2022-2025 | |
| Pfizer INC. | $305.74 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $256.67 | 2023-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $242.26 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Celltrion USA INC. | $231.85 | 2023-2025 | Vegzelma, Zymfentra |
| Janssen Biotech, INC. | $180.40 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $171.79 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $166.22 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $147.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $133.51 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $129.55 | 2023-2024 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $98.93 | 2022-2024 | Talicia |
| Ipsen Biopharmaceuticals, INC | $85.07 | 2024-2025 | Iqirvo, Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.13 | 2023-2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $61.55 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $55.64 | 2023 | |
| Ironwood Pharmaceuticals, INC | $47.50 | 2024 | |
| Braintree Laboratories, INC. | $32.97 | 2023-2024 | Suflave, Sutab |
| Mallinckrodt Hospital Products INC. | $29.86 | 2023 | Terlivaz |
| Exact Sciences Corporation | $23.42 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $22.70 | 2023 | Accrufer |
| Novo Nordisk INC | $20.60 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $18.41 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.95 | 2023 | Sotyktu |
| Celgene Corporation | $17.13 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.